Total item
Cart Subtotal
$0.00 c-MET
| Catalog No. | Inhibitor Name | c-Met | Other |
|---|---|---|---|
| A10712 | Crizotinib | * | ALK |
| A10996 | Cabozantinib | *** | VEGFR2/KDR,Kit,VEGFR3/FLT4 |
| A10998 | Foretinib | **** | KDR,Tie-2,VEGFR3/FLT4 |
| A10713 | PHA-665752 | ** | RON,Flk1,c-Abl |
| A10869 | SU11274 | ** | Flk1,RON,FGFR1 |
| A10839 | SGX-523 | *** | |
| A10153 | BMS-777607 | *** | Axl,RON,Tyro3 |
| A11087 | Tivantinib | * | |
| A10493 | JNJ-38877605 | *** | |
| A10711 | PF-04217903 | ** | |
| A10587 | MGCD-265 | **** | RON,VEGFR2,VEGFR1 |
| A11132 | Capmatinib | **** | |
| A11059 | BMS-754807 | ** | Insulin Receptor,IGF-1R,TrkB |
| A10154 | BMS-794833 | *** | VEGFR2 |
| A10063 | AMG-208 | ** | |
| A11753 | MK-2461 | **** | c-Met (Y1235D),c-Met (Y1230C),c-Met (N1100) |
| A11396 | Golvatinib | * | VEGFR2 |
| A11055 | AMG-458 | **** | VEGFR2 |
| A11257 | Tepotinib | *** | IRAK4,TrkA,Axl |
| A11150 | NVP-BVU972 | * | |
| A12557 | Merestinib | *** | |
| A15917 | NPS-1034 | * | Axl |
| A11489 | MK-8033 | **** | Ron |
| A14387 | Altiratinib | *** | TIE-2, VEGFR |
| A14419 | Volitinib (Savolitinib, AZD-6094) | ||
| A15792 | BMS-817378 | *** | VEGFR2 |
Notes:
1.Hover mouse over "" to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of "" is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
35 Item(s)
per page
-
LY2801653 (Merestinib)
Catalog No. A12557 c-MET inhibitorLY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM). Learn More -
LY2801653 dihydrochloride
Catalog No. A15150 MET inhibitorLY2801653 dihydrochloride is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM). Learn More -
PF-04217903 methanesulfonate
Catalog No. A15208 c-Met InhibitorPF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant). Learn More -
BMS-817378
Catalog No. A15792 MET/VEGFR-2 inhibitorBMS-817378 is a novel prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833. Learn More -
INCB28060
Catalog No. A11132 c-MET InhibitorINCB28060, a novel inhibitor of c-MET kinase. INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines. Learn More -
Altiratinib (DCC2701)
Catalog No. A14387 c-Met/VEGFR inhibitorAltiratinib is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. Learn More -
ARQ 197 (Tivantinib)
Catalog No. A11087 c-Met inhibitorARQ-197 is a selective inhibitor of the c-Met receptor tyrosine kinase Learn More -
BMS-754807
Catalog No. A11059 IGF-1R inhibitorBMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents. Learn More -
NPS-1034
Catalog No. A15917 c-Met inhibitorNPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively. Learn More -
c-Met inhibitor 2
Catalog No. A16256 c-Met inhibitorc-Met inhibitor 2 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor. Learn More -
Glesatinib hydrochloride
Catalog No. A16257 MET/Axl inhibitorGlesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered. Learn More -
PF-2341066 (Crizotinib)
Catalog No. A10712 ALK/ c-Met inhibitorPF-2341066 (Crizotinib) is an inhibitor of the c-Met kinase and the NPM-ALK. PF-2341066 inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM). Learn More -
Foretinib (GSK1363089, XL880)
Catalog No. A10998 c-MET inhibitorForetinib (GSK1363089), a multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces Anoikis, and impairs ovarian cancer metastasis. Learn More -
XL184 free base (Cabozantinib)
Catalog No. A10996 VEGFR inhibitorXL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2. Learn More -
BMS 777607
Catalog No. A21638 c-Met/Axl/Ron/Tyro3 inhibitorBMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. Learn More -
MK-8033
Catalog No. A11489 c-Met inhibitorMK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer. Learn More -
AMG 337
Catalog No. A16400 MET inhibitorAMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor. Learn More -
Glumetinib (SCC-244)
Catalog No. A18328 c-Met inhibitorGlumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC50 of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin. Learn More -
JNJ-38877618
Catalog No. A18325 c-Met inhibitorJNJ-38877618 is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively. Learn More -
S49076
Catalog No. A21407 MET, AXL/MER, and FGFR1/2/3 inhibitorS49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM. Learn More -
c-Met inhibitor 1
Catalog No. A15049 c-Met inhibitorc-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer. Learn More -
Volitinib (Savolitinib, AZD-6094)
Catalog No. A14419 c-Met inhibitorVolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Learn More -
E-7050 (Golvatinib)
Catalog No. A11396 E7050 (also known as golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. Learn More -
MK-2461
Catalog No. A11753 c-Met InhibitorMK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Learn More -
NVP-BVU972
Catalog No. A11150 -
AMG-458
Catalog No. A11055 c-Met inhibitorAMG-458 is a potent inhibitor of c-Met with an IC50 value of 60nM and displays selectivity against VEGFR2. Learn More -
BMS-794833
Catalog No. A10154 c-Met inhibitorBMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol. Learn More -
AMG 208
Catalog No. A10063 c-Met InhibitorAMG 208 is a novel c-Met inhibitor that inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity. Learn More -
PF-04217903
Catalog No. A10711 c-Met InhibitorPF-04217903 is a novel c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors. Learn More -
MGCD-265 (Glesatinib)
Catalog No. A10587 c-Met inhibitorMGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R. Learn More -
BMS-777607
Catalog No. A10153 c-Met inhibitorBMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway. Learn More -
JNJ-38877605
Catalog No. A10493 c-Met inhibitorc-Met inhibitor JNJ-38877605 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. Learn More -
SGX-523
Catalog No. A10839 c-Met InhibitorSGX-523 is an orally bioavailable small molecule, specifically binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway. Learn More -
PHA-665752
Catalog No. A10713 c-Met InhibitorPHA665752 is a small-molecule inhibitor of c-Met/HGF/SF signaling. Learn More -
SU11274
Catalog No. A10869
35 Item(s)
per page
FILTER BY:
Shopping Options
- Actions
-
- Inhibitor (34)
Adooq Quality Guarantee
We promise all products perform as described.